The central target of $14 is the arithmetic mean of three current, attributable analyst price targets: Canaccord Genuity (John Newman) at $13 with a Buy rating, reiterated in October 2026; Mizuho Securities (Salim Syed) at $18 with a Buy rating, maintained in August 2026; and Freedom Capital Markets at $10 with a Hold rating, set when the firm upgraded the stock from Sell in May 2026. Summed and divided by three, these produce a mean of $13.67, rounded to $14. The low-to-high range is $10 to $18, a wide spread that signals meaningful disagreement about the probability of U.S. approval for the company's lead therapy.
The bullish view hinges on tab-cel (tabelecleucel), an allogeneic T-cell immunotherapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disease (PTLD). Canaccord's May upgrade from Hold to Buy, which raised its target from $6 to $13, cited a positive FDA Type A meeting and a potential approval pathway. Freedom Broker's upgrade from Sell to Hold, with a target raised from $4 to $10, reflected a similar shift, with the firm describing the probability of U.S. approval as "high" after an agreement on the design of a new filing. The cautious view, represented by the lower target, weighs the company's thin cash position and execution risk.
As of late October 2026, ATRA traded near $8.30, with a 52-week range of roughly $3.92 to $19.15 and a market capitalization around $83 million. Reaching $14 from $8.30 implies an upside of approximately 69%, a very large move by any standard and one that would require a material re-rating of the shares.
The path toward that level runs almost entirely through a single binary event: FDA action on the resubmitted tab-cel BLA. Atara resubmitted the application in late September 2026, and the FDA accepted it for review in mid-October. Approval would unlock milestone and royalty payments from the company's European commercialization partner, Pierre Fabre, potentially transforming the company's financial profile. The alternative is a second Complete Response Letter, which would likely pressure the stock back toward its 52-week low.
The shares have been consolidating below the 50-day simple moving average near $9.25 and the 200-day exponential moving average near $9.16, while holding above the 200-day simple moving average near $7.63. The $10 round-number level, which coincides with the lowest analyst target, marks an initial psychological hurdle, while the 52-week high near $19.15 sits above even the highest target. A durable support zone appears near $7.63, and a sustained move through the low-$9 range would be a necessary first step toward any re-rating toward the central target.
Analyst price targets generally reflect a research horizon of about 12 months, though each firm applies its own assumptions. For a story driven by a single regulatory decision, the effective catalyst timeline may be shorter. Investors should monitor the FDA review timeline and any communication from Atara or Pierre Fabre, the company's next earnings report, updates on cash runway and financing plans, and any revisions to analyst targets or ratings. Changes to the approval timeline, additional data requests from the FDA, or new financing announcements would be the most consequential developments.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like ATRA, these signals can help traders spot shifts in momentum and identify opportunities or deteriorating trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how automated analysis can support your own monitoring process.
Can Atara Biotherapeutics (ATRA) reach $14? The central target is the rounded mean ($13.67) of three analyst price targets spanning $10 to $18, and it implies a roughly 69% gain from the latest price near $8.30. The case for the move rests almost entirely on a successful FDA review of tab-cel, which would unlock milestone and royalty economics through Pierre Fabre. The case against it rests on a fragile cash position, minimal revenue, and the binary nature of the regulatory outcome. The wide analyst range underscores the uncertainty. Investors should focus on the FDA review timeline, cash runway, and any changes to analyst targets rather than treating the $14 figure as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ATRA has been loosely correlated with PHAT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRA jumps, then PHAT could also see price increases.
| Ticker / NAME | Correlation To ATRA | 1D Price Change % | ||
|---|---|---|---|---|
| ATRA | 100% | +5.87% | ||
| PHAT - ATRA | 36% Loosely correlated | +3.05% | ||
| LXEO - ATRA | 34% Loosely correlated | -2.55% | ||
| INVA - ATRA | 33% Poorly correlated | -0.94% | ||
| MOLN - ATRA | 31% Poorly correlated | -5.80% | ||
| AUTL - ATRA | 31% Poorly correlated | -6.58% | ||
More | ||||